Guangdong T&K Pharmaceutical Co., Ltd.

Guangdong Taienkang Pharmaceutical Co., Ltd., established in 1999 with stock code 301263, is a comprehensive pharmaceutical innovation enterprise focusing on R&D, production, sales and agent operation of pharmaceutical products and medical devices and providing pharmaceutical technology services and transfer. The core products include "Fishing Pill IV", "Aitingjiu" Dapoxetine Hydrochloride tablets, "Jolethin" Lecithin Complex Lodine tablets, etc. Regarding R&D innovation, Taienkang insists on independent R&D of medicines as a key measure to enhance core competitiveness. Subsidiaries Shandong Hubble Kisen Biotechnology Co., Ltd. and Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. are the two major R&D centers of Taienkang. Hubble Kisen has built three R&D technology platforms, including a functional excipients and nano-medicine delivery technology platform, a biological macromolecular medicine technology platform, and a generic medicine development and consistency evaluation technology platform; Bochuangyuan is mainly engaged in the R&D and industrialization of Category 1.1 innovative medicines in the field of dermatology. It has a large number of technical reserves and strong technological innovation capabilities in the R&D of therapeutic medicines for vitiligo, atopic dermatitis, etc. Among them, CKBA, a category 1.1 innovative medicine for the treatment of vitiligo, has officially launched phase Il clinical trials. This innovative medicine will fill the gap in the domestic vitiligo medicine market and is expected to become a blockbuster product with annual sales exceeding 10 billion.